Blood coagulation disease
MONDO:0001531A condition in which there is a deviation from or interruption of the normal coagulation properties of the blood.
Also known as: blood coagulation disorder, coagulation defect, coagulation disorder, coagulation disorder, blood, coagulation disorders, blood, coagulopathy, disorder, blood coagulation, disorders, blood coagulation
518 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Clotting drug may replace plasma transfusions in heart surgery
Disease control TerminatedThis study compared two treatments to reduce bleeding after heart valve surgery: a concentrated clotting drug (PCC) versus fresh frozen plasma (FFP). The trial planned to enroll 476 adults undergoing elective valve surgery. It was terminated early, so the full comparison was not …
Phase: PHASE4 • Sponsor: SHI Jia • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Gene-Edited cells aim to stop bleeding in severe hemophilia b
Disease control TerminatedThis early-stage trial tests a one-time treatment called BE-101 for adults with severe hemophilia B. The therapy uses a person's own blood cells, modified with CRISPR gene editing, to continuously produce the missing clotting factor. The goal is to reduce or prevent bleeding epis…
Phase: PHASE1, PHASE2 • Sponsor: Be Biopharma • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Tailored drug regimen shows promise for rare blood disorder
Disease control TerminatedThis study tested whether giving the drug caplacizumab based on regular blood tests (ADAMTS13 activity) could improve outcomes for adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare condition causing dangerous blood clots. The trial enrolled 58 adults and mon…
Phase: PHASE2 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Hemophilia drug study falls short: only 3 patients enrolled before termination
Disease control TerminatedThis study aimed to see if a new medicine (efanesoctocog alfa) helps people with moderate or severe hemophilia A reach their personal goals and be more physically active. It planned to enroll 35 people aged 12 to 50, but was stopped early after only 3 joined. The medicine is used…
Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Can extra care after transplant help older patients live better?
Disease control TerminatedThis study tested two extra care programs—supportive palliative care and clinical management of other health issues—for older or frail patients who had a donor stem cell transplant. The goal was to see if these programs could improve quality of life and survival compared to stand…
Phase: PHASE2, PHASE3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Promising aHUS drug trial stalls after only 6 patients enrolled
Disease control TerminatedThis study tested a drug called narsoplimab (OMS721) for atypical hemolytic uremic syndrome (aHUS), a rare condition that causes blood clots and organ damage. The trial aimed to see if the drug could improve platelet counts and was safe for adults and adolescents. However, the st…
Phase: PHASE3 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Experimental drug iptacopan tested for rare blood disorders
Disease control TerminatedThis study tested an experimental drug called iptacopan in people with two rare blood disorders: immune thrombocytopenia (ITP) and cold agglutinin disease (CAD). The goal was to see if the drug could improve platelet counts in ITP or hemoglobin levels in CAD. The trial was termin…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Cancer drug combo shows promise for Hard-to-Treat bowel cancer
Disease control TerminatedThis study tested a combination of two drugs, atezolizumab and bevacizumab, in 46 people with advanced colorectal cancer that had stopped responding to chemotherapy and had a specific genetic feature called MSI-like. The goal was to see if the treatment could shrink tumors. The s…
Phase: PHASE2 • Sponsor: Vall d'Hebron Institute of Oncology • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Could home blood tests transform hemophilia care? study seeks patient views
Knowledge-focused TerminatedThis study looked at how patients with hemophilia A or those on blood thinners feel about monitoring their blood clotting at home. Researchers interviewed 19 people to understand their needs and hopes for a new device that could measure clotting factors. The goal was to gather in…
Sponsor: Radboud University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Simple blood test may predict Post-Surgery clot risk
Knowledge-focused TerminatedThis pilot study aimed to see if a blood test called thromboelastography (TEG) and platelet mapping could predict clotting or bleeding complications after non-cardiac surgery. The study included 200 patients who were taking aspirin or clopidogrel for at least 10 days before elect…
Sponsor: McMaster University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Tiny study on clotting disorder and artery health ends early
Knowledge-focused TerminatedThis study aimed to see if women with thrombophilia (a condition that makes blood clot more easily) have differences in artery function compared to healthy women. Researchers planned to measure blood vessel dilation and other artery health markers. However, the study was terminat…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC